Arbutus Biopharma Quick Ratio (ABUS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Arbutus Biopharma Corp  (NASDAQ: ABUS)

Arbutus Biopharma's Quick Ratio

ABUS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.39 below Arbutus Biopharma Corp average.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Quick Ratio than Arbutus Biopharma in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 163 to 773.

Explain Quick Ratio?
How much Cash & cash equivalents ABUS´s has?
What are ABUS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ABUS/financial-strength
https://api.csimarket.com/api/v1/companies/ABUS/fundamentals
https://api.csimarket.com/api/v1/companies/ABUS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ABUS Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 4199.5 %
Y / Y Cash & cash equivalent Change 1402.03 %
Quick Ratio MRQ 1.39
ABUS's Total Ranking # 773
Seq. Current Liabilities Change 6648.48 %
Seq. Cash & cash equivalent Change 1660.33 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 180
Healthcare Sector # 291
Overall Market # 773


Quick Ratio Statistics
High Average Low
20.07 8.18 0.84
(Mar 31 2020)   (Dec 31 2011)




Financial Statements
Arbutus Biopharma's Current Liabilities $ 242 Millions Visit ABUS's Balance sheet
Arbutus Biopharma's Cash & cash equivalent $ 337 Millions Visit ABUS's Balance sheet
Source of ABUS's Sales Visit ABUS's Sales by Geography


Cumulative Arbutus Biopharma's Quick Ratio

ABUS's Quick Ratio for the trailling 12 Months

ABUS Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 429.81 %
Y / Y Cash & cash equivalent TTM Growth 198.76 %
Quick Ratio TTM 1.54
Total Ranking TTM # 3620
Seq. Current Liabilities TTM Growth 1028.8 %
Seq. Cash & cash equivalent TTM Growth 377.47 %

Quick ratio ranking by company, industry and sector >> Back to ABUS Financial Strength Comparisons >> Go to Compare ABUS Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2026 to $241.93 millions, cumulative Quick Ratio decreased to 1.54 below the Arbutus Biopharma Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Arbutus Biopharma. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2442 to 3620.

Explain Quick Ratio?
How much Cash & cash equivalents ABUS´s has?
What are ABUS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 424
Healthcare Sector # 866
Within the Market # 3620


trailing twelve months Quick Ratio Statistics
High Average Low
13.67 4.98 1.09
(Mar 31 2016)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Cingulate Inc   3.58 $ 23.186  Millions$ 6.484  Millions
Xilio Therapeutics Inc   3.47 $ 122.182  Millions$ 35.258  Millions
Corbus Pharmaceuticals Holdings Inc   3.30 $ 115.337  Millions$ 34.967  Millions
Maia Biotechnology Inc   3.30 $ 21.339  Millions$ 6.474  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Talphera Inc   3.06 $ 14.157  Millions$ 4.630  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Nextcure Inc   2.95 $ 8.728  Millions$ 2.960  Millions
Pyxis Oncology Inc   2.79 $ 55.572  Millions$ 19.942  Millions
Zenas Biopharma Inc   2.78 $ 177.778  Millions$ 64.043  Millions
Ptc Therapeutics inc   2.74 $ 2,127.918  Millions$ 776.076  Millions
Annexon Inc   2.72 $ 102.389  Millions$ 37.660  Millions
Turn Therapeutics Inc   2.71 $ 9.433  Millions$ 3.479  Millions
Beone Medicines Ltd   2.67 $ 5,955.905  Millions$ 2,233.923  Millions
Biohaven Ltd   2.57 $ 161.125  Millions$ 62.767  Millions
Altimmune inc   2.51 $ 28.888  Millions$ 11.526  Millions
Ironwood Pharmaceuticals inc   2.49 $ 86.376  Millions$ 34.733  Millions
Azitra Inc   2.44 $ 3.751  Millions$ 1.540  Millions
Tg Therapeutics Inc   2.43 $ 632.004  Millions$ 260.526  Millions
Adc Therapeutics Sa  2.42 $ 189.204  Millions$ 78.125  Millions
Dermata Therapeutics Inc   2.40 $ 4.822  Millions$ 2.012  Millions
Vistagen Therapeutics Inc   2.38 $ 20.034  Millions$ 8.429  Millions
Opko Health Inc   2.37 $ 384.036  Millions$ 162.356  Millions
Pacira Biosciences inc   2.31 $ 295.577  Millions$ 128.209  Millions

Date modified: 2026-11-11T13:30:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.